Results 141 to 150 of about 466,743 (315)

Neoplasias de células linfoides maduras B: avaliação dos casos diagnosticados e acompanhados no hospital universitário da Universidade Federal de Santa Catarina entre 2011 e 2014 [PDF]

, 2015
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2015.De acordo com a classificação da OMS (2008), as neoplasias de células maduras B (NCLM-B) abrangem os ...
Cardoso, Chandra Chiappin
core  

Composite Lymphoma: EBV-positive Classic Hodgkin Lymphoma and Peripheral T-cell Lymphoma A Case Report

, 2009
Composite lymphomas are rare and defined as hematopoietic neoplasms with more than I malignant lymphomatous clone showing different phenotypic features.
Berg, Anke Van Den, Weiss, Lawrence M., Bacchi, Carlos E., Van Den Berg, Anke; id_orcid, Gualco, Gabriela, Van Den Berg, Anke, Chioato, Lucimara   +6 more
core   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

Advanced Science, EarlyView.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei, Xiangsheng Liu   +10 more
wiley   +1 more source

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party

, 1991
Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma.
Leonard, R C, Hayward, R.L., Prescott, Robin J   +2 more
core  

The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

Zhongguo aizheng zazhi, 2019
Background and purpose: For patients with relapsed or refractory B-cell lymphoma, conventional therapy is not effective. Researching new treatment technology to improve prognosis is imminent.
勋, 张锡友, 峰, 李丹丹, 董倩倩, 宋清坤, 钟晓松, 李文斌   +7 more
doaj  

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source

Ultra-deep mutational analysis of NPM-ALK and possible implications on target therapy in anaplastic large cell lymphoma of childhood [PDF]

, 2013
Anaplastic Large Cell Lymphoma (ALCL) represents a distinct subset of aggressive T-cell non-Hodgkin lymphoma (NHL) accounting for about 3% of adult NHL and 10 to 15% of childhood lymphomas.
Lovisa, Federica
core  

DTX3L Inhibits the EMT, Metastasis, and Stem‐Like Features of Gastric Cancer Through Promoting GSK‐3β Dependent SNAI1 Decay

Advanced Science, EarlyView.
This research identifies DTX3L as a critical tumor suppressor that inhibits epithelial‐mesenchymal transition (EMT), invasion and metastasis in gastric cancer. By functioning as an E3 ubiquitin ligase, DTX3L targets the master EMT regulator SNAI1 for GSK‐3β‐dependent proteasomal degradation.
Yang Chen, Zhen Li, Jiajia Shen, Jingyu Lin, Xiaoli Zhao, Rui Zhang, Ying Han, Zhen Wang   +7 more
wiley   +1 more source

Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy

Blood Science
Anti-CD19 chimeric antigen receptor T cells (CAR T) still have many limitations, including insufficient clinical efficacy. Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor with higher drug potency, and it is not clear whether it
Hao Yao, Ling Qiu, Shi-Hui Ren, Dan Chen, Meng-Jiao Li, Bai-Tao Dou, Nan Zhang, Xiao Wang, Yi Su, Alex H. Chang, Fang-Yi Fan   +10 more
doaj   +1 more source

Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma

Advanced Science, EarlyView.
This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...
Xingyue Yang, Baoshuai Liang, Liangmin Fu, Weiliang Deng, Yuyan Jiang, Weiping Xu, Jinwei Chen, Ya Zhou, Ke Wu, Jiaguo Huang   +9 more
wiley   +1 more source